With respect to NSCLC, the non-ATP competitive and selective MEK1 and MEK2 inhibitor U0126 has been proven to attenuate Paclitaxel-induced apoptosis [64]. This evidence concerns the gene MAP2K2 and non-small cell lung carcinoma.